Tai­wan's Ace­po­dia clos­es Se­ries B with the promise of con­ju­gat­ing an­ti­bod­ies and off-the-shelf NK cells

What if re­searchers could take the an­ti­body-drug con­ju­gate mod­el and ap­ply it to off-the-shelf NK cell ther­a­py? For the Tai­wan-based biotech Ace­po­dia, that’s the $47 mil­lion ques­tion.

Ace­po­dia closed its Se­ries B round Tues­day morn­ing, hop­ing to build up­on CEO Son­ny Hsiao’s work from when he was a bi­ol­o­gist at UC Berke­ley. The biotech plans to use the funds to ad­vance its lead pro­gram through the end of a Phase I tri­al and launch a Phase II study, as well as to get two oth­er can­di­dates in­to the clin­ic.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN